SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently drawing intense community focus as traders debate the sustainability of its push toward the 75k level, fueled by steady ETF inflows and aggressive whale accumulation. While some market participants express skepticism about the longevity of the current momentum amid geopolitical uncertainty, the prevailing sentiment remains centered on the asset's structural strength and its role as a hedge against global financial volatility.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is facing significant volatility and community debate as investors weigh the potential impact of pending regulatory clarity and institutional infrastructure developments against persistent price stagnation. The community remains deeply polarized, with bullish sentiment fueled by rumors of institutional adoption and ETF speculation clashing with bearish concerns over token dilution and the asset's historical correlation to broader market trends.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently the subject of intense debate among market participants as the asset tests critical support levels amid shifting institutional interest and broader geopolitical tensions. The community remains highly polarized, with active discussions focused on the launch of new staking ETFs, concerns over institutional accumulation, and divergent technical outlooks regarding potential breakout or retest scenarios.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant market buzz as investors eye a potential breakout, fueled by institutional staking interest and its emerging role as a core infrastructure layer for the growing AI agent economy. Community discussion is dominated by bullish sentiment regarding Solana's scalability and its resilience in the face of ongoing macroeconomic uncertainty and sector-wide volatility.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing intense market scrutiny and volatility following reports of a delayed rollout for its 'Avocado' AI model, leading to heightened concerns over the company's massive capital expenditures and ability to compete with rivals. While some investors view the pullback as a buying opportunity based on long-term efficiency through proprietary AI chip development, the broader community remains divided, with active discussions focusing on whether these costly infrastructure bets will ultimately deliver sufficient revenue growth or lead to further margin compression.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community engagement and sentiment driven by its positioning as a global cultural asset on the Solana blockchain. Supporters are rallying around the brands mission to unify the cannabis movement through digital infrastructure, while buzz builds ahead of seasonal industry milestones and ongoing discussions regarding global policy reform.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing heightened volatility and intense community debate as investors weigh the stock's role as a traditional safe haven against a stronger US dollar, rising oil prices, and ongoing geopolitical instability in the Middle East. While some market participants are liquidating positions amidst shifting rate expectations and inflation uncertainty, others are aggressively accumulating physical metals, viewing the current market turbulence as a critical long-term hedge against systemic financial risks.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment remains volatile as investors closely monitor escalating geopolitical tensions in the Middle East and their impact on global oil prices and supply chain stability. The community is actively debating the durability of current market levels, with traders split between calls for a potential short-squeeze rally and warnings of further downside risk driven by energy uncertainty.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending due to massive institutional Bitcoin accumulation driven by the success of its STRC issuance and Michael Saylor's ongoing aggressive buying strategy, which has sparked intense debate over the stock's role as a leveraged Bitcoin proxy. Market participants are actively discussing the potential for a short squeeze amidst record volume, while community members remain deeply divided between those betting on generational wealth through a "supply shock" and skeptics who view the firm's dilution tactics as a precarious, debt-fueled house of cards.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members rally behind a "hopecore" narrative, highlighting significant engagement across social media platforms like TikTok and YouTube. Investors are actively discussing the token's long-term potential, focusing on accumulation strategies and building conviction despite broader market volatility.

statis crypto Watchlist

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Equity

<ul class="summary-bullets"><li>UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain.</li><li>The FDA recently said that data from uniQure’s Phase I/II trials were not sufficient and recommended a new randomized Phase III study.</li><li>RBC Capital estimates a 50% chance of eventual approval as Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130.</li></ul>Shares of uniQure N.V. (QURE) surged more than 20% on Monday, following upgrades from Wall Street firms, citing a potentially improving regulatory outlook for its Huntington’s disease therapy.Wells Fargo upgraded the company to ‘Overweight’ from ‘Equal Weight’ and sharply raised its price target to $60 from $15, according to The Fly. This implies a 243% potential rise from its current price of around $17.5.<h2 class="st-heading-2">Vinay Prasad’s Reported Departure In Spotlight</h2>Wells Fargo said the outlook for uniQure’s experimental gene therapy AMT-130 could improve following reports that Vinay Prasad will leave the U.S. Food and Drug Administration (FDA) next month. Prasad, who serves as both the Chief Medical and Scientific Officer and the Director of the Center for Biologics Evaluation and Research at the FDA, is set to leave next month, according to a Bloomberg report on Friday.Wells Fargo also noted that strong criticism from the media and the Huntington’s disease community over the FDA’s call for a new Phase 3 trial highlights stakeholder support for the therapy. That backing could strengthen the drug’s chances during review, approval, and commercialization.AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. It uses a virus to deliver genetic instructions that help lower the protein. The treatment is administered directly into the striatum, an area of the brain heavily affected by Huntington’s disease, through a surgical procedure.Separately, RBC Capital Markets upgraded uniQure to ‘Outperform’ from ‘Sector Perform’ and raised its price target to $35 from $11. The firm said Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130, estimating about a 50% chance of eventual approval.<h2 class="st-heading-2">FDA Seeks New Randomized Study</h2>The upgrades come after regulatory uncertainty weighed on the company earlier this year. The FDA recently said that data from uniQure’s Phase I/II trials were insufficient to support a marketing application and recommended that the company conduct a new randomized Phase III study, including a controversial sham surgery control group.uniQure has raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit. The company plans to request another meeting with the FDA in the second quarter of 2026 to discuss potential study designs.Despite the regulatory debate, AMT-130 has shown promising early data. In an earlier study, patients receiving a high dose of the gene therapy experienced about a 75% slower rate of disease progression after three years, along with a slower decline in both motor function and cognitive ability.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp rally, retail sentiment for <a href="https://stocktwits.com/symbol/QURE">QURE</a> on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to surge to $150 if the company receives the FDA approval.<stembedurl>https://stocktwits.com/ChineseTakeeout/message/646975511</stembedurl>Another user weighed the options present for short sellers and long-term investors.<stembedurl>https://stocktwits.com/sepsis74/message/646972082</stembedurl>The stock has declined nearly 28% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/saudi-arabia-begins-slashing-oil-production-tpet-batl-indo-shares-continue-to-draw-retail-buzz/cZdVlsWRIIj">Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Stocks Continue To Draw Retail Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

<ul class="summary-bullets"><li>Results showed that BXCL501 helped reduce withdrawal symptoms and could be as effective as or better than lofexidine.</li><li>Patients receiving BXCL501 experienced more than a 30% reduction in withdrawal symptoms.</li><li>BioXcel said BXCL501 could also be well-suited for treating withdrawal from opioids adulterated with xylazine.</li></ul>Shares of BioXcel Therapeutics Inc (BTAI) gave up early gains to trade 5% higher on Thursday, after the company announced positive topline results from a Phase 2 trial evaluating BXCL501 for treating opioid withdrawal symptoms.Results of the study, which involved 80 patients, showed that BXCL501 helped reduce withdrawal symptoms and may be as effective as or better than lofexidine, an FDA-approved treatment for opioid withdrawal.&nbsp;<h2 class="st-heading-2">BXCL501 Treatment Shows 30% Reduction In Withdrawal Symptoms</h2>Patients receiving BXCL501 experienced more than a 30% reduction in withdrawal symptoms, with the strongest improvement seen on days three and four of treatment. The drug also showed a favorable safety and tolerability profile, with lower rates of certain cardiovascular side effects and no reports of sedation in the treatment groups.These findings build on the company’s earlier Phase 1b/2 RELEASE study, which established the tolerability of selected BXCL501 doses in opioid-dependent patients, and expand the results to a different clinical setting that included a methadone taper and an active comparator.BXCL501 could also be well-suited for treating withdrawal from opioids adulterated with xylazine, the company added.“Opioid withdrawal remains a significant burden on the healthcare system and patients, and despite available therapies, there is still a substantial unmet need for safe and more effective treatment options that can help patients successfully transition to other medications such as buprenorphine or naltrexone for long-term benefits,” said Sandra Comer, Principal Investigator of the study and Professor of Neurobiology in the Department of Psychiatry at Columbia University. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/BTAI">BTAI</a> flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user highlighted the company’s debt situation.<stembedurl>https://stocktwits.com/Just_An_Investor/message/646712839</stembedurl>Year-to-date, the stock has gained around 7%For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment? 

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?

<ul class="summary-bullets"><li>The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition, the company said.</li><li>In January, Codexis tied up with Axolabs to evaluate its ECO Synthesis platform.</li><li>The firm is expected to post its Q4 results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million.</li></ul>Shares of Codexis, Inc. (CDXS) gained 7% on Wednesday after the company announced an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform.Codexis, however, did not disclose the name of the firm.The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition. Codexis’ ECO Synthesis platform is built to enable scalable, high-fidelity production of complex siRNA therapies.As RNA-based medicines move beyond rare diseases into larger patient populations, manufacturing requirements are rising significantly. The company believes its enzymatic technology is well-positioned to meet this growing demand.&nbsp;“We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity,” said Alison Moore, President and Chief Executive Officer of Codexis.<h2 class="st-heading-2">Axolabs Partnership For ECO Synthesis Platform</h2>The news follows Codexis’ agreement earlier this year with Axolabs to evaluate its ECO Synthesis platform, a step that could lead to future licensing opportunities and wider adoption of the technology in RNA manufacturing.Kathleen Campau, Senior Director of Operations at Axolabs, had said that the technology could play a pivotal role in the future large-scale manufacturing of therapeutic oligonucleotides by enabling more sustainable and cost-effective production.The biotech firm is expected to post its fourth-quarter results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million, according to Fiscal.ai data, while loss is expected to narrow to $0.04 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CDXS">CDXS</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user believes the latest development adds “momentum and validation.”<stembedurl>https://stocktwits.com/Camille65/message/646560686</stembedurl>Another user noted they were neutral earlier but turned bullish on the stock after reading the announcement.<stembedurl>https://stocktwits.com/10xMoonstocks/message/646571515</stembedurl>The stock has been under heavy selling pressure this year, declining more than 36%Read also: &nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-coreweave-perplexity-cloud-partnership/cZd9F11RI5u">CoreWeave Inks Deal With Perplexity – CRWV Stock Gains 6% Pre-Market, On Track To Arrest Post Earnings Slump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Did CDXS Stock Jump 7% Today?

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

<ul class="summary-bullets"><li>McCutcheon said findings presented for VIR-5500 surpassed expectations and strengthened Vir’s standing among therapies in prostate cancer.</li><li>He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen.</li><li>Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20.</li></ul>Vir Biotechnology Inc. (VIR) received a pair of bullish calls from Wall Street after unveiling fresh clinical data and a sizable new drug partnership, prompting analysts to raise their ratings and price targets on the stock.On Monday, the company reported strong fourth-quarter earnings and encouraging Phase 1 results for its cancer therapy study.&nbsp;<h2 class="st-heading-2">Raymond James Upgrades Vir Biotechnology</h2>Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12 following the series of corporate updates, according to TheFly.&nbsp;According to McCutcheon, findings presented for VIR-5500 surpassed expectations and strengthened its standing among PSMA-directed T-cell engager therapies in prostate cancer.He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen combining tobevibart and elebsiran, which he believes has a viable regulatory path.<a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology stock</a> traded over 60% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_071715_png_bf610d177d.webp" alt="VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="926" height="103"><figcaption>VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>Separately, Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20 while maintaining an ‘Overweight’ rating. Ulz said early-stage data for VIR-5500 reinforce its potential to emerge as a leading treatment option in prostate cancer.<h2 class="st-heading-2">New Partnership Adds Financial Backing</h2>Vir also announced a collaboration with Astellas Pharma that includes $335 million in upfront and near-term payments. The agreement outlines a 50/50 profit split in the U.S. and royalty payments on sales outside the country, providing additional capital and shared commercialization support.The partnership will co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.&nbsp;Vir is eligible to earn up to $1.37 billion in additional development, regulatory, and sales milestones.VIR stock has declined by over 21% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-is-bringing-mac-mini-production-to-texas-now/cZRvveYR4zD">Apple Is Bringing Mac Mini Production To Texas Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

<ul class="summary-bullets"><li>Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense.</li><li>R&amp;D expense for the quarter increased by $28.7 million to $63.9 million.</li><li>The company remains focused on completing enrollment in its BCG-naïve randomized trial and targeting a BLA filing by Q4 2026, CEO said.</li></ul>Shares of ImmunityBio, Inc. (IBRX) drew investor focus in pre-market trading on Monday after the pharmaceutical firm reported better-than-expected fourth-quarter results.The stock gained 11% with <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">ANKTIVA Boosts Q4 Revenue</h2>Net product revenue for Q4 surged 431% to $38.3 million, above Wall Street’s estimates of $37.8 million, according to Fiscal.ai data. ImmunityBio cited the increase in revenue to the sales of ANKTIVA, a U.S. Food and Drug Administration (FDA) approved immunotherapy for bladder and lung cancer.However, Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense, the company said. R&amp;D expense for the quarter increased by $28.7 million to $63.9 million."As we advance toward initial international commercial activities, we remain focused on disciplined execution: completing enrollment in our BCG-naïve randomized trial with a BLA filing targeted by Q4&nbsp;2026, expanding the ANKTIVA label into lung cancer and lymphopenia, and converting our 700%&nbsp;revenue growth trajectory into durable, long-term value for shareholders," said Richard Adcock, President and CEO of ImmunityBio.<h2 class="st-heading-2">Anktiva Expansion Plans</h2>Earlier on Monday, Chairman Soon-Shiong <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us/amp">said</a> on X that a detailed press release about a three-year expansion plan for the BioShield platform, including Anktiva, is expected to be released.&nbsp;He described it as a strong start to the year and discussed Anktiva’s IL-15 science, noting its importance in natural killer cell therapies. He added that IL-15 has long been viewed as a promising cancer-fighting cytokine and said Anktiva now uses it effectively.ImmunityBio has partnered with Biopharma and Cigalah Healthcare to launch Anktiva in Saudi Arabia and expand across the MENA region. The drug recently won approvals in Saudi Arabia and the European Union, bringing total approvals to 33 countries.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for IBRX on Stocktwits remained in the 'extremely bullish' zone, amid 'extremely high' message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/IBRX_jpg_a6c9147f3c.webp" alt="IBRX.jpg" width="934" height="109"><figcaption>IBRX's Sentiment Meter and Message Volumes on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>One user compared the stock to AAPL, stating that they were "adding aggressively."<stembedurl>https://stocktwits.com/BixbyKnolls/message/645637611</stembedurl>Another user expected a bigger rally.<stembedurl>https://stocktwits.com/Guitars7/message/645634938</stembedurl>Year-to-date, the stock has surged around 380%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tirx-stock-tian-ruixiang-rally-business-combination/cZRtvrnR4yl">This Nano-Cap Stock Shot Up 130% Today – What Triggered The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBB News

IBBiShares Biotechnology ETF